Pharming (PHAR) Income from Continuing Operations (2020 - 2026)
Pharming's (PHAR) quarterly Income from Continuing Operations came in at $147000.0 in Q2 2026, up 103.77% quarter-over-quarter from -$3.9 million in Q1 2026.
Powered by 
Analysis
Pharming (PHAR) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pharming (PHAR) has reported Income from Continuing Operations for 7 consecutive years, with $147000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations changed N/A year-over-year to $147000.0; the trailing twelve-month figure through Jun 2026 stood at $14.1 million (changed N/A YoY), and the FY2025 full-year result was $2.5 million, up 121.43% from the prior year.
- Income from Continuing Operations advanced to $147000.0 in Q2 2026 per PHAR's latest filing, from -$3.9 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $37.9 million in Q4 2022 and bottomed at -$20.8 million in Q1 2023.
- Historically, Income from Continuing Operations has averaged -$1.1 million across 5 years, with a median of $4.3 in 2025.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 485.2% in 2023, then surged 345.94% in 2025.
- Over 5 years, Income from Continuing Operations stood at $37.9 million in 2022, then tumbled by 135.56% to -$13.5 million in 2023, then fell by 16.5% to -$15.7 million in 2024, then jumped by 100.0% to $4.3 in 2025, then soared by 3418504.65% to $147000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $147000.0, -$3.9 million, and $4.3 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -782.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 601.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Pharming | 740.27 Mn | 580.77 Mn | 141.47 Mn | 147,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 147,000.00 |
| Mar 31, 2026 | -3.90 Mn |
| Dec 31, 2025 | 4.30 |
| Sep 30, 2025 | 17.90 Mn |
| Mar 31, 2025 | -8.39 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | 4.01 Mn |
| Jun 30, 2024 | -19.70 Mn |
| Mar 31, 2024 | -20.28 Mn |
| Dec 31, 2023 | -13.48 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | -15.69 Mn |
| Mar 31, 2023 | -20.80 Mn |
| Dec 31, 2022 | 37.90 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 5.40 Mn |
| Dec 31, 2021 | 15.19 Mn |
| Sep 30, 2021 | -17.81 Mn |
| Jun 30, 2021 | 12.22 Mn |